CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $11.51M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
347.20MUSDvs all stocks (USD)
Revenue (TTM)
11.51MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.5550xvs all stocks
52-Week Change
153.00%vs all stocks
Market Capitalization
347.20MUSDvs all stocks (USD)
Enterprise Value
251.48MUSDvs all stocks (USD)
Forward P/E
-7.06xvs Biotechnology peers
Price to Sales (TTM)
30.16xvs Biotechnology peers
Enterprise to Revenue
21.85xvs Biotechnology peers
Enterprise to EBITDA
-5.70xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-207.40%vs Biotechnology peers
Return on Assets (TTM)
-25.39%vs Biotechnology peers
Revenue (TTM)
11.51MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.14USDUpdated Sep 28, 2026Quarterly Revenue Growth
408.60%vs Biotechnology peers
Gross Profit (TTM)
-23.07MUSDvs all stocks (USD)
EBITDA (TTM)
135.09MUSDvs all stocks (USD)
Net Income (TTM)
-324.56MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
26.20%vs Biotechnology peers
Operating Cash Flow (TTM)
-34.76MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-21.75MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.48MUSDFY2025 · Dec 31, 2025Operating Income
-42.09MUSDvs all stocks (USD)
Pre-tax Income
-242.03MUSDFY2025 · Dec 31, 2025Net Income
-242.03MUSDFY2025 · Dec 31, 2025EBIT
-42.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
135.09MUSDFY2025 · Dec 31, 2025Research & Development
29.36MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
16.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.02MUSDFY2025 · Dec 31, 2025EPS (Basic)
-32.37USDFY2025 · Dec 31, 2025EPS (Diluted)
-32.37USDFY2025 · Dec 31, 2025Basic Shares Outstanding
7.48MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
7.48MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-242.03MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-164.82MUSDFY2025 · Dec 31, 2025Free Cash Flow
-164.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
89.93MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-242.03MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
537.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.83MUSDFY2025 · Dec 31, 2025Other Non-cash Items
72.12MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.33MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
142.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-128.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-128.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
83.78MUSDFY2025 · Dec 31, 2025Shares Outstanding
11.75MSharesUpdated Sep 28, 2026Float Shares
4.62MSharesUpdated Sep 28, 2026Shares Short
2.20MSharesUpdated Sep 28, 2026Short Ratio
11.97daysvs all stocks
Short % of Shares Outstanding
33.64%vs all stocks
% Held by Insiders
3.14%vs all stocks
% Held by Institutions
104.86%vs all stocks
Total Cash (MRQ)
102.04MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.68USDUpdated Sep 28, 2026Total Debt (MRQ)
6.32MUSDvs all stocks (USD)
Current Ratio (MRQ)
12.14xvs Biotechnology peers
Book Value per Share (MRQ)
-18.60USDUpdated Sep 28, 2026Total Assets
98.73MUSDvs all stocks (USD)
Total Current Assets
91.56MUSDFY2025 · Dec 31, 2025Total Liabilities
286.49MUSDFY2025 · Dec 31, 2025Total Non-current Assets
7.17MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
276.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
89.25MUSDFY2025 · Dec 31, 2025Accounts Receivable
0.00USDFY2025 · Dec 31, 2025Accounts Payable
728.00KUSDFY2025 · Dec 31, 2025Short-term Debt
1.29MUSDFY2025 · Dec 31, 2025Other Current Liabilities
289.00KUSDFY2025 · Dec 31, 2025Long-term Debt
5.35MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
158.66MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-527.28MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-187.76MUSDvs all stocks (USD)
52-Week Low
11.39USDUpdated Sep 28, 202652-Week High
37.83USDUpdated Sep 28, 202652-Week Change
153.00%vs all stocks
Beta
0.5550xvs all stocks
50-Day MA
21.88USDUpdated Sep 28, 2026200-Day MA
24.36USDUpdated Sep 28, 2026Avg 10-Day Volume
1.47MSharesUpdated Sep 28, 2026Avg 30-Day Volume
614.20KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-40.06USDUpdated Sep 28, 2026Other Income / Expense
-202.95MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $11.51M, lower than 95% of all stocks globallySignificant
Revenue (USD): 11,511,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Youkeshu Technology Co. Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Heilongjiang Publishing & Media Co. Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Fastly Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC